MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 3, 2006; DOI: 10.1124/mol.105.019240


0026-895X/06/6906-2084-2092$20.00
Mol Pharmacol 69:2084-2092, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.019240v1
69/6/2084    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nagar, S.
Right arrow Articles by Blanchard, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagar, S.
Right arrow Articles by Blanchard, R. L.

Sulfotransferase (SULT) 1A1 Polymorphic Variants *1, *2, and *3 Are Associated with Altered Enzymatic Activity, Cellular Phenotype, and Protein Degradation

Swati Nagar1, Susan Walther2, and Rebecca L. Blanchard

Fox Chase Cancer Center, Philadelphia, Pennsylvania

The superfamily of sulfotransferase (SULT) enzymes catalyzes the sulfate conjugation of several pharmacologically important endo- and xenobiotics. SULT1A1 catalyzes the sulfation of small planar phenols such as neurotransmitters, steroid hormones, acetaminophen, and p-nitrophenol (PNP). Genetic polymorphisms in the human SULT1A1 gene define three alleles, SULT1A1*1, *2, and *3. The enzyme activities of the SULT1A1 allozymes were studied with a variety of substrates, including PNP, 17beta-estradiol, 2-methoxyestradiol, catecholestrogens, the antiestrogen 4-hydroxytamoxifen (OHT), and dietary flavonoids. Using purified recombinant SULT1A1 protein, marked differences in *1, *2, and *3 activity toward every substrate studied were noted. Substrate inhibition was observed for most substrates. In general, the trend in Vmax estimates was *1 > *3 > *2; however, Vmax/Km estimate trends varied with substrate. In MCF-7 cells stably expressing either SULT1A1*1 or *2, the antiestrogenic response to OHT was found to be allele-specific: the cells expressing *2 exhibited a better antiproliferative response. The intracellular stability of the *1 and *2 allozymes was examined in insect as well as mammalian cells. The SULT1A1*2 protein had a shorter half-life than the *1 protein. In addition, the *2 protein was ubiquitinated to a greater extent than *1, suggesting increased degradation via a proteasome pathway. The results of this study suggest marked differences in activity of polymorphic SULT1A1 variants, including SULT1A1*3, toward a variety of substrates. These differences are potentially critical for understanding interindividual variability in drug response and toxicity, as well as cancer risk and incidence.


Received for publication September 26, 2005.

Accepted for publication March 2, 2006.

Address correspondence to: Rebecca L. Blanchard, Merck and Co., Inc., 5 Sentry Parkway, BLB-33, Blue Bell, PA 19422. E-mail: rebecca_blanchard{at}merck.com




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
L. Wang, N. Raghavan, K. He, J. M. Luettgen, W. G. Humphreys, R. M. Knabb, D. J. Pinto, and D. Zhang
Sulfation of O-Demethyl Apixaban: Enzyme Identification and Species Comparison
Drug Metab. Dispos., April 1, 2009; 37(4): 802 - 808.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
H. Sun, L. Zhang, E. C. Y. Chow, G. Lin, Z. Zuo, and K. S. Pang
A Catenary Model to Study Transport and Conjugation of Baicalein, a Bioactive Flavonoid, in the Caco-2 Cell Monolayer: Demonstration of Substrate Inhibition
J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 117 - 126.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
J. A. Williams, T. Andersson, T. B. Andersson, R. Blanchard, M. O. Behm, N. Cohen, T. Edeki, M. Franc, K. M. Hillgren, K. J. Johnson, et al.
PhRMA White Paper on ADME Pharmacogenomics
J. Clin. Pharmacol., July 1, 2008; 48(7): 849 - 889.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. M. Furimsky, C. E. Green, L. E. H. Sharp, P. Catz, A. A. Adjei, T. Parman, I. M. Kapetanovic, R. M. Weinshilboum, and L. V. Iyer
Effect of Resveratrol on 17 -Estradiol Sulfation by Human Hepatic and Jejunal S9 and Recombinant Sulfotransferase 1E1
Drug Metab. Dispos., January 1, 2008; 36(1): 129 - 136.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
D. Ung and S. Nagar
Variable Sulfation of Dietary Polyphenols by Recombinant Human Sulfotransferase (SULT) 1A1 Genetic Variants and SULT1E1
Drug Metab. Dispos., May 1, 2007; 35(5): 740 - 746.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
T. R. Rebbeck, A. B. Troxel, Y. Wang, A. H. Walker, S. Panossian, S. Gallagher, E. G. Shatalova, R. Blanchard, G. Bunin, A. DeMichele, et al.
Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk.
J Natl Cancer Inst, September 20, 2006; 98(18): 1311 - 1320.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics